Metastatic Hepatocellular Carcinoma Pipeline Landscape Covering Therapeutic Assessment and Drug Portfolio in 2017
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver, responsible for significant morbidity and mortality worldwide. Inventions in technologies for cancer treatment procedures are expected to launch into the market in the coming years. Moreover, the increasing investment of pharmaceutical companies in the research and development of anti-cancer drugs would contribute to the growth of hepatocellular carcinoma treatment market. A new pipeline study, related to the therapeutics activities for Metastatic Hepatocellular Carcinoma has been recently broadcasted to...
View full press release